700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ ReadersThis Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
|Michael D Wagener|
|Stellar Bio molecular Research (SBR) and FCTI, Germany|
|Keynote: J Nephrol Ther|
|Phosphatidylcholine is a phospholipid that is one of the main components of lecithin. Lecithin is found in all cell membranes and plays a major role in maintaining the fluidity of the cell by affecting what enters and leaves the cell through the cell membrane. Given as infusion, PC might improve many conditions, among them kidney function and overall energy. Clinical studies have been performed in glomerulonephritis, where a reduction of edema could be observed. Also in renal insufficiency patients showed an increase in creatinine, urine volume and renal clearance when receiving PC intravenously. Overall patients suffering from fatigue from various causes (e.g. Chronic Kidney Disease) were benefiting from phosphatidylcholine infusions. Standard toxicological assessments indicate no significant acute or chronic toxicity from PC, as well as no mutagenicity and no teratogenicity.|
Michael D Wagener has received a Medical Degree from the University of Berlin, Germany, in 1991. During his Post-graduate training, he was trained in General Internal Medicine, Pneumology and Allergology in Davos (Switzerland). He received board certification in General Internal Medicine, Allergology and Pharmaceutical Medicine and Neuraltherapy. In 1997, he joined Eli Lilly as a Clinical Research Physician, in 2005 Novartis Pharma in Basel and in 2009 he became Chief Medical Officer of AC Immune in Lausanne (Switzerland). Since 2000, he was a member of the Executive Board of the Swiss Association of Pharmaceutical Medicine (SGPM) and in 2002 to 2008 he was elected President of this Organization. Since 2010, he is the Owner of an “Antiaging and Complementary Medicine Center” in Basel.
Email: [email protected]
|PDF | HTML|